Skip to main content

Table 4 Patient consumption profile and Human Health benefit and burden results

From: Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections

1. Patient consumption profile TI PP1M PP3M
Syringes (1 M) 8055 94
Syringes (3 M) 2564
GP visits 2883 3322 3447
Psychiatrist visits 34,109 35,224 35,528
Ambulatory care visits 1849 701 371
General hospital bed days 791 335 178
Psychiatric hospital bed days 43,864 16,406 8699
2. Human Health benefit
Years Lived with Disability (YLD)
Total patient YLDs 626.80 603.49 596.90
ΔYLDs of treatment vs. TI (%) −23.31 (−3.72%) −29.91 (−4.77%)
Years of Life Lost (YLL)
Total patient YLLs 346.23 300.63 288.36
ΔYLL of treatment vs. TI (%) −45.60 (−13.17%) −57.87 (−16.71%)
Disability-Adjusted Life Years (DALY) = YLD + YLL
Total patient DALYs 973.03 904.12 885.26
ΔDALY of treatment vs. TI (%) −68.91 (−7.08%) −87.77 (−9.02%)
Quality-Adjusted Life Years (QALY)
Total patient QALYs 785.22 830.54 881.35
ΔQALY of treatment vs. TI (%) + 45.32 (+ 5.77%) + 96.13 (+ 12.24%)
3. Human Health burden
Environmental DALYs
Total environmental DALYs 0.954 0.579 0.468
ΔDALYs of treatment vs. TI (%) −0.375 (−39.32%) −0.487 (−51.00%)
4. Net Human Health effects (net DALYs = YLD + YLL + environmental DALYs)
Total net DALYs 973.98 904.70 885.73
ΔDALY of treatments vs. TI −69.29 (−7.11%) −88.26 (−9.06%)
  1. Abbreviations: PP1M, paliperidone palmitate once-monthly injection; PP3M, paliperidone palmitate three-monthly injection; TI, Treatment Interruption